gpcr-antibodies
(2)
Antiverse
Antiverse is a UK-based AI-driven biotech that designs functional therapeutic antibodies against targets long considered 'undruggable' - notably G-protein coupled receptors (GPCRs), ion channels, and other transmembrane proteins where conventional antibody discovery routinely fails. Its platform pairs generative AI models, trained for years on the hardest antibody targets, with a proprietary 'lab-in-the-loop' wet lab using engineered cell lines and deep sequencing, taking a target to an optimized antibody in roughly four months. Founded in 2017 and headquartered in Cardiff, Wales, the company works through pharma partnerships and licensing (e.g. Nxera Pharma) alongside its own internal pipeline and non-profit collaborations such as the Cystic Fibrosis Foundation.
Surge Biswas
Surge Biswas is the co-founder and CEO of Nabla Bio, a Cambridge, Massachusetts biotech that designs antibodies with AI. As a graduate student in George Church's Harvard lab he helped pioneer protein language modeling, a technique now central to machine-learning-guided protein design. At Nabla he built JAM, a generative system he calls 'molecular auto-complete' that designs therapeutic antibodies from a target sequence alone, including against notoriously undruggable membrane proteins like GPCRs. The company has raised roughly $37M and struck collaborations with Takeda, AstraZeneca, and Bristol Myers Squibb worth over a billion dollars in potential payments.